Renalytix AI Targets Profitability with Kidney Test Sales

Renalytix AI (GB:RENX) has released an update.

Renalytix AI reports a strategic shift towards commercial sales with its FDA-approved kidneyintelX.dkd test, now covered by Medicare at $950 per test. This move, alongside significant debt reduction and fresh funding of £11.8m, positions the company for profitability within two years. With kidney disease affecting millions, Renalytix aims to revolutionize early-stage diagnosis and treatment, driving both improved patient outcomes and financial stability.

For further insights into GB:RENX stock, check out TipRanks’ Stock Analysis page.